Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 3/2014

01-12-2014 | Letter to the Editor

Investigation of glucose intolerance in patients with normocalcemic primary hyperparathyroidism: 4-year follow-up

Authors: Halit Diri, Kursad Unluhizarci, Fahrettin Kelestimur

Published in: Endocrine | Issue 3/2014

Login to get access

Excerpt

Dear Editor, …
Literature
1.
H. Lowe, D.J. McMahon, M.R. Rubin, J.P. Bilezikian, S.J. Silverberg, Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J. Clin. Endocrinol. Metab. 92, 3001–3005 (2007)PubMedCrossRef
2.
M.R. Rubin, S.J. Silverberg, Glucose intolerance and primary hyperparathyroidism: an unresolved relationship. Endocrine 42, 231–233 (2012)PubMedCrossRef
3.
I. Cakir, K. Unluhizarci, F. Tanriverdi, G. Elbuken, Z. Karaca, F. Kelestimur, Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism. Endocrine 42, 419–422 (2012)PubMedCrossRef
4.
F. Tassone, M. Maccario, L. Gianotti, C. Baffoni, M. Pellegrino, S. Cassibba, F. Cesario, G. Magro, G. Borretta, Insulin sensitivity in normocalcaemic primary hyperparathyroidism. Endocrine 44, 812–814 (2013)PubMedCrossRef
5.
M. Procopio, M. Barale, S. Bertaina, S. Sigrist, R. Mazzetti, M. Loiacono, G. Mengozzi, E. Ghigo, M. Maccario, Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms. Endocrine (2013). doi:10.​1007/​s12020-013-0091-z PubMed
6.
C. Lorenzo, L.E. Wagenknecht, R.B. D’Agostino Jr, M.J. Rewers, A.J. Karter, S.M. Haffner, Insulin resistance, beta cell dysfunction, and conversion to type 2 diabetes in a multiethnic population. The ınsulin resistance atherosclerosis study. Diabetes Care 33, 67–72 (2010)PubMedCentralPubMedCrossRef
Metadata
Title
Investigation of glucose intolerance in patients with normocalcemic primary hyperparathyroidism: 4-year follow-up
Authors
Halit Diri
Kursad Unluhizarci
Fahrettin Kelestimur
Publication date
01-12-2014
Publisher
Springer US
Published in
Endocrine / Issue 3/2014
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0263-5

Other articles of this Issue 3/2014

Endocrine 3/2014 Go to the issue

Editorial

Strict rules are needed for validation of G-protein-coupled receptor immunohistochemical studies in human tissues

Meta-Analysis

Selenium supplementation and the risk of type 2 diabetes mellitus: a meta-analysis of randomized controlled trials

Endocrine Genetics/Epigenetics

Polymorphisms in NR3C1 gene associated with risk of metabolic syndrome in a Chinese population

Research Letter

Optimizing waist circumference cut-points for the metabolic syndrome in a South African cohort at 3-year follow-up: the SABPA prospective cohort

Review

Treatment of body composition changes in obese and overweight older adults: insight into the phenotype of sarcopenic obesity

Original Article

The follicular outcome after standard gonadotropin stimulation is associated with ERα and ERβ genotypes
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits